ConductScience.org, home

Comparison · NCT00282984-da327b7b

Varenicline (Var) vs Placebo (Pbo): Number of Responders With Continuous Abstinence (CA) Through Week 24

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Varenicline (Var) vs Placebo (Pbo): Number of Responders With Continuous Abstinence (CA) Through Week 24. Trial comparisons, record NCT00282984-da327b7b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00282984-da327b7b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2830.2390.332wilson
Risk in group 20.09710.07040.133wilson
Risk difference, group 1 minus group 20.1860.1290.242newcombe hybrid score
Risk ratio, group 1 over group 22.922.034.18log
Odds ratio, group 1 over group 23.672.415.61log
Number needed to treat, for one more participant with the outcome on Varenicline (Var) than on Placebo (Pbo)5.374.137.74from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Varenicline (Var)
1 week titration followed by 11 weeks of 1 milligram (mg) twice daily (BID) dosing. Study medication was discontinued at the Week 12 visit and participants' smoking status was followed through the non-treatment period to Week 52.
100353OG000
Group 2Placebo (Pbo)
1 week titration followed by 11 weeks of placebo (pbo). Study medication was discontinued at the Week 12 visit and participants' smoking status was followed through the non-treatment period to Week 52.
34350OG001

Outcome

Type
SECONDARY
Title
Number of Responders With Continuous Abstinence (CA) Through Week 24
Description
Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) Has participant smoked any cigarettes (even a puff) since the last contact? = No AND 2) Has participant used any other tobacco products… since the last contact? = No. Non- responder if the expired CO \> 10 ppm at any given timepoint.
Time frame
Week 9 through Week 24
Population
All Participants population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
NCT number
NCT00282984
Phases
PHASE3
Conditions
Smoking Cessation
Interventions
placebo, Varenicline
Lead sponsor
Pfizer
Results first posted
2009-04-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00282984-da327b7b